Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C6H5NO2
CAS Number:
Molecular Weight:
123.11
UNSPSC Code:
12352207
NACRES:
NA.71
PubChem Substance ID:
EC Number:
200-441-0
Beilstein/REAXYS Number:
109591
MDL number:
product line
BioReagent
Quality Level
assay
≥98%
form
powder
mol wt
Mw 123.11 g/mol
technique(s)
cell culture | insect: suitable, cell culture | mammalian: suitable, cell culture | plant: suitable
color
white to off-white
pH
3.4 (20 °C, 10 g/L)
mp
236-239 °C (lit.)
solubility
1 M NaOH: soluble 50 mg/mL, clear, colorless to very faintly yellow
density
1.473 g/cm3 at 25 °C
application(s)
agriculture
SMILES string
OC(=O)c1cccnc1
InChI
1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChI key
PVNIIMVLHYAWGP-UHFFFAOYSA-N
Gene Information
human ... CYP1A2(1544)
rat ... Chrnb2(54239)
Still not finding the right product?
Explore all of our products under Nicotinic acid
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
379.4 °F - closed cup
flash_point_c
193 °C - closed cup
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Beat Müller et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 20(2), 181-195 (2003-10-11)
A novel methodology for establishing a pharmacological dose-effect relationship of methyl nicotinate, hexyl nicotinate and nicotinic acid acting as peripheral vasodilators in the skin following topical application is investigated. This methodology involves the estimation of the unbound drug concentration in
Paul M Lavigne et al.
Journal of the American College of Cardiology, 61(4), 440-446 (2012-12-26)
This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
Koon K Teo et al.
Stroke, 44(10), 2688-2693 (2013-07-25)
In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
Global Trade Item Number
| SKU | GTIN |
|---|---|
| N0761-100G | 04061834093060 |
